{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:06:03Z","timestamp":1792371963623,"version":"4.4.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Left ventricular (LV) hypertrophy contributes to the onset and progression of heart failure (HF), particularly for patients with pre-HF (stage B) for whom no treatment has yet proven effective to prevent transition to overt HF (stage C). The \u03b2<jats:sub>3<\/jats:sub>-adrenergic receptors (\u03b23ARs) may represent a new target, as their activation attenuates LV remodeling.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine whether activation of \u03b23ARs by repurposing a \u03b23AR agonist, mirabegron, is safe and effective in preventing progression of LV hypertrophy and diastolic dysfunction among patients with pre- or mild HF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The Beta3-LVH prospective, triple-blind, placebo-controlled phase 2b randomized clinical trial enrolled patients between September 12, 2016, and February 26, 2021, with a follow-up of 12 months. The trial was conducted at 10 academic hospitals in 8 countries across Europe (Germany, Poland, France, Belgium, Italy, Portugal, Greece, and the UK). Patients aged 18 years or older with or without HF symptoms (maximum New York Heart Association class II) were screened for the presence of LV hypertrophy (increased LV mass index [LVMI] of \u226595 g\/m<jats:sup>2<\/jats:sup> for women or \u2265115 g\/m<jats:sup>2<\/jats:sup> for men) or maximum wall thickness of 13 mm or greater using echocardiography. Data analysis was performed in August 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Participants were randomly assigned (1:1) to mirabegron (50 mg\/d) or placebo, stratified by the presence of atrial fibrillation and\/or type 2 diabetes, for 12 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end points were LVMI determined using cardiac magnetic resonance imaging and LV diastolic function (early diastolic tissue Doppler velocity [E\/e\u2032] ratio assessed using Doppler echocardiography) at 12 months. Patients with at least 1 valid measurement of either primary end point were included in the primary analysis. Safety was assessed for all patients who received at least 1 dose of study medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 380 patients screened, 296 were enrolled in the trial. There were 147 patients randomized to mirabegron (116 men [79%]; mean [SD] age, 64.0 [10.2] years) and 149 to placebo (112 men [75%]; mean [SD] age, 62.2 [10.9] years). All patients were included in the primary intention-to-treat analysis. At 12 months, the baseline and covariate-adjusted differences between groups included a 1.3-g\/m<jats:sup>2<\/jats:sup> increase in LVMI (95% CI, \u22120.15 to 2.74; <jats:italic>P<\/jats:italic>\u2009=\u2009.08) and a \u22120.15 decrease in E\/e\u2032 (95% CI, \u22120.69 to 0.4; <jats:italic>P<\/jats:italic>\u2009=\u2009.60). A total of 213 adverse events (AEs) occurred in 82 mirabegron-treated patients (including 31 serious AEs in 19 patients) and 215 AEs occurred in 88 placebo-treated patients (including 30 serious AEs in 22 patients). No deaths occurred during the trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this study, mirabegron therapy had a neutral effect on LV mass or diastolic function over 12 months among patients who had structural heart disease with no or mild HF symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02599480\">NCT02599480<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2023.3003","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T15:10:24Z","timestamp":1695222624000},"page":"1031","source":"Crossref","is-referenced-by-count":17,"title":["Repurposing the \u03b2<sub>3<\/sub>-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease"],"prefix":"10.1001","volume":"8","author":[{"given":"Jean-Luc","family":"Balligand","sequence":"first","affiliation":[{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulce","family":"Brito","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisboa, Portugal"},{"name":"Centro Acad\u00e9mico de Medicina de Lisboa, Universidade de Lisboa, Lisboa, Portugal"},{"name":"Faculdade de Medicina, Centro Cardiovascular, Universidade de Lisboa, Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Brosteanu","sequence":"additional","affiliation":[{"name":"Clinical Trial Centre Leipzig, Universit\u00e4t Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Casadei","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, Oxford, United Kingdom"},{"name":"National Institute of Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Depoix","sequence":"additional","affiliation":[{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Edelmann","sequence":"additional","affiliation":[{"name":"Department of Cardiology, German Centre for Cardiovascular Research, Charit\u00e9 University Campus Virchow, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Gerber","sequence":"additional","affiliation":[{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Gruson","sequence":"additional","affiliation":[{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hasenclever","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics, Statistics, and Epidemiology, Universit\u00e4t Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Hellenkamp","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pneumology, German Centre for Cardiovascular Research, Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignatios","family":"Ikonomidis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Krakowiak","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre for Heart Diseases, Clinical Military Hospital, Wroc\u0142aw Medical University, Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Lhommel","sequence":"additional","affiliation":[{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masliza","family":"Mahmod","sequence":"additional","affiliation":[{"name":"Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Neubauer","sequence":"additional","affiliation":[{"name":"Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Persu","sequence":"additional","affiliation":[{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Piechnik","sequence":"additional","affiliation":[{"name":"Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkert","family":"Pieske","sequence":"additional","affiliation":[{"name":"Department of Cardiology, German Centre for Cardiovascular Research, Charit\u00e9 University Campus Virchow, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Pieske-Kraigher","sequence":"additional","affiliation":[{"name":"Department of Cardiology, German Centre for Cardiovascular Research, Charit\u00e9 University Campus Virchow, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisboa, Portugal"},{"name":"Centro Acad\u00e9mico de Medicina de Lisboa, Universidade de Lisboa, Lisboa, Portugal"},{"name":"Faculdade de Medicina, Centro Cardiovascular, Universidade de Lisboa, Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre for Heart Diseases, Clinical Military Hospital, Wroc\u0142aw Medical University, Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, University of Milano-Bicocca, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-No\u00ebl","family":"Trochu","sequence":"additional","affiliation":[{"name":"Institut du Thorax, Centre National de la Recherche Scientifique, Nantes Universit\u00e9, Nantes, France"},{"name":"L\u2019Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Centre Hospitalier Universitaire de Nantes, Nantes Universit\u00e9, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Van Overstraeten","sequence":"additional","affiliation":[{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Wachter","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pneumology, German Centre for Cardiovascular Research, Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany"},{"name":"Department of Cardiology, University Hospital Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Catherine","family":"Pouleur","sequence":"additional","affiliation":[{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"hoi230043r1","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure: a contemporary perspective.","volume":"128","author":"Roger","year":"2021","journal-title":"Circ Res"},{"issue":"18","key":"hoi230043r2","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001062","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"hoi230043r3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.v23.3","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association.","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"hoi230043r4","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"hoi230043r5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"hoi230043r6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"hoi230043r7","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the Soluble Guanylate Cyclase Stimulator in Heart Failure Patients With Preserved EF (SOCRATES-PRESERVED) study.","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur Heart J"},{"issue":"15","key":"hoi230043r8","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial.","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"hoi230043r9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10741-020-10042-0","article-title":"Mechanisms underlying the pathophysiology of heart failure with preserved ejection fraction: the tip of the iceberg.","volume":"26","author":"Miranda-Silva","year":"2021","journal-title":"Heart Fail Rev"},{"issue":"12","key":"hoi230043r10","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.3390\/cells9122584","article-title":"The beta3 adrenergic receptor in healthy and pathological cardiovascular tissues.","volume":"9","author":"Michel","year":"2020","journal-title":"Cells"},{"issue":"7","key":"hoi230043r11","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1172\/JCI2191","article-title":"The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle.","volume":"102","author":"Gauthier","year":"1998","journal-title":"J Clin Invest"},{"issue":"4","key":"hoi230043r12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.113.004940","article-title":"Enhanced expression of \u00df3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase.","volume":"129","author":"Belge","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"hoi230043r13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrcardio.2017.224","article-title":"Nitric oxide signalling in cardiovascular health and disease.","volume":"15","author":"Farah","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"hoi230043r14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.pharmthera.2010.02.002","article-title":"Sympathetic nervous activation in obesity and the metabolic syndrome\u2014causes, consequences and therapeutic implications.","volume":"126","author":"Lambert","year":"2010","journal-title":"Pharmacol Ther"},{"issue":"1","key":"hoi230043r15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/nau.v33.1","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"hoi230043r16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/ehf2.v5.5","article-title":"Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease: Beta3-Left Ventricular Hypertrophy (Beta3-LVH).","volume":"5","author":"Pouleur","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"1","key":"hoi230043r17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"issue":"4","key":"hoi230043r18","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance.","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"issue":"17","key":"hoi230043r19","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jacc.2011.06.054","article-title":"Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise Training in Diastolic Heart Failure) pilot study.","volume":"58","author":"Edelmann","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi230043r21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ejhf.2017.19.issue-4","article-title":"The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial.","volume":"19","author":"Bundgaard","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"hoi230043r22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009120","article-title":"Hemodynamic effects of cyclic guanosine monophosphate-dependent signaling through \u00df3 adrenoceptor stimulation in patients with advanced heart failure: a randomized invasive clinical trial.","volume":"15","author":"Bundgaard","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"3","key":"hoi230043r23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ejhf.v25.3","article-title":"\u00df3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial.","volume":"25","author":"Garc\u00eda-\u00c1lvarez","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"hoi230043r24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"hoi230043r25","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.","volume":"4","author":"Kosmala","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"hoi230043r26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12968-021-00805-5","article-title":"Morphological and functional cardiac consequences of rapid hypertension treatment: a cohort study.","volume":"23","author":"Jordan","year":"2021","journal-title":"J Cardiovasc Magn Reson"},{"issue":"36","key":"hoi230043r27","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","article-title":"A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.","volume":"41","author":"Brown","year":"2020","journal-title":"Eur Heart J"},{"issue":"12","key":"hoi230043r28","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1161\/01.CIR.103.12.1649","article-title":"Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium.","volume":"103","author":"Moniotte","year":"2001","journal-title":"Circulation"},{"issue":"15","key":"hoi230043r29","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121510","article-title":"Human adipose beiging in response to cold and mirabegron.","volume":"3","author":"Finlin","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"hoi230043r30","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1172\/JCI134892","article-title":"The \u00df3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans.","volume":"130","author":"Finlin","year":"2020","journal-title":"J Clin Invest"},{"issue":"5","key":"hoi230043r31","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1172\/JCI131126","article-title":"Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity.","volume":"130","author":"O\u2019Mara","year":"2020","journal-title":"J Clin Invest"},{"key":"hoi230043r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2022.100674","article-title":"Selectivity and maximum response of vibegron and mirabegron for \u00df3-adrenergic receptors.","volume":"96","author":"Brucker","year":"2022","journal-title":"Curr Ther Res Clin Exp"},{"issue":"5","key":"hoi230043r33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/1756287215591763","article-title":"Clinical use of the \u00df3 adrenoceptor agonist mirabegron in patients with overactive bladder syndrome.","volume":"7","author":"Vij","year":"2015","journal-title":"Ther Adv Urol"},{"issue":"3","key":"hoi230043r34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.kint.2016.03.020","article-title":"\u00df3 adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function.","volume":"90","author":"Procino","year":"2016","journal-title":"Kidney Int"},{"issue":"10","key":"hoi230043r35","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrurol.2017.113","article-title":"Pharmacology: cardiovascular effects of mirabegron.","volume":"14","author":"Andersson","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"2","key":"hoi230043r36","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1093\/ehjci\/jeab154","article-title":"Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging.","volume":"23","author":"Smiseth","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"hoi230043r20","volume-title":"Applied Longitudinal Analysis","author":"Fitzmaurice","year":"2004"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2809846\/jamacardiology_balligand_2023_oi_230043_1698258706.33956.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T16:05:34Z","timestamp":1699459534000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2809846"}},"subtitle":["The Beta3-LVH Phase 2b Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.3003","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}